Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Adynxx Announces Merger Agreement with Alliqua BioMedical and Provides Business and Clinical Update | ||
By: Nasdaq / GlobeNewswire - 22 Apr 2019 | Back to overview list |
|
Adynxx announced plans to merge with Alliqua BioMedical and become a Nasdaq-listed public company in early 2019 Company announced receipt of substantial grant award from the National Institute on Drug Abuse to support the clinical development of brivoligide, a novel drug candidate intended to reduce both postoperative pain and the need for opioid-based therapies Company also announced plans to initiate two Phase 2 studies of brivoligide in postoperative pain with topline results expected in 2020 SAN FRANCISCO, April 22, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of pain and inflammatory diseases, today provided a business and clinical development update. Business Highlights and Recent Developments
Clinical Development Update
“The Adynxx team has made tremendous progress advancing the AYX platform of non-opioid pain therapies and in securing non-dilutive funding to further support the ongoing development of brivoligide, the company’s lead product candidate,” said Dennis Podlesak, Adynxx’s Chairman and Partner of Domain Associates. “Given the ongoing opioid crisis in the United States, we believe brivoligide has the potential to transform the treatment paradigm for post-operative pain and importantly play a significant role in reducing the need for addictive opioid-based therapies.” About Adynxx A recognized leader in transcription factor decoy technology, Adynxx is utilizing its platform of AYX transcription factor decoys to create first-in-class therapies with disease-modifying properties. Transcription factor decoys are short, synthetic double-stranded DNA oligonucleotides that bind to transcription factors and prevent their interaction with the genome, effectively inhibiting a coordinated network of pathologic gene expression. The AYX platform has applications across multiple disease states and has initially been leveraged to create novel, non-opioid therapeutics for the treatment of pain. About Brivoligide Clinical studies suggest that a single administration of brivoligide at the time of surgery can safely reduce pain for weeks, accelerate the time to achieve mild pain, and substantially reduce the need for opioid use during recovery specifically in patients at greater risk of experiencing increased and prolonged pain following surgery. Brivoligide (formerly AYX1) is an intrathecally-administered, 23 base-pair, double-stranded DNA transcription factor decoy oligonucleotide. It inhibits the transcription factor EGR1 in the dorsal root ganglia and spinal cord at the time of surgery. EGR1 binds to the promoter regions of many genes associated with nociceptive sensitization and increased pain. EGR1 launches waves of gene regulation at the time of surgery that initiate and maintain neuronal sensitization. This sensitization may lead to increased and prolonged postoperative pain in certain patients who are relatively insensitive to analgesics and may be at high risk for elevated use of rapidly acting opioids, the type most commonly associated with Opioid Use Disorder or OUD. View source version on: Source: Adynxx, Inc. Investors: Media: |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |